Prevalence of hepatitis B, tetanus, hepatitis A, human immunodeficiency virus and feasibility of vaccine delivery among injecting drug users in Bangkok, Thailand, 2003-2005

Addiction

Volumn 103, Issue 10, 2008, Pages 1687-1695

  Sunthornchart, Sunthorn ^a   Linkins, Robert W ^b,c   Natephisarnwanish, Voranut ^a   Levine, William C ^c   Maneesinthu, Kunyarat ^a   Lolekha, Rangsima ^b   Tappero, Jordan W ^b,c   Trirat, Nisanart ^a   Muktier, Suchada ^b   Chancharastong, Pennapa ^a   Fox, Kimberley ^b,c   Donchalermpak, Suwanna ^a   Vitek, Charles ^c   Supawitkul, Somsak ^b  

^a Bangkok Metropolitan Administration   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Hepatitis A and B; HIV; Immunization; Injection drug users; Tetanus

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS B ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; TETANUS ANTIBODY;

ADULT; AGE; AGED; ANTIBODY DETECTION; ARTICLE; FEMALE; HEPATITIS A; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; SEROPREVALENCE; TETANUS; THAILAND; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CROSS-SECTIONAL STUDIES; EPIDEMIOLOGIC STUDIES; FEASIBILITY STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS A; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SUBSTANCE ABUSE, INTRAVENOUS; TETANUS; THAILAND; VACCINATION;

EID: 51249101874     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2008.02303.x     Document Type: Article

References (36)

1. Centers for Disease Control and Prevention (CDC). Hepatitis B vaccination for injection drug users - Pierce County, Washington, 2000. MMWR 2001 50:388 90.
2. Centers for Disease Control and Prevention (CDC). HBV virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood immunization: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991 40:1 19.
3. Centers for Disease Control and Prevention (CDC). Update: recommendations to prevent HBV virus transmission - United States. MMWR 1999 48:33 4.
4. Centers for Disease Control and Prevention (CDC). Viral Hepatitis and Injection Drug Users, September 2002. Available at: http://www.cdc.gov/idu/ hepatitis/viral_hep_drug_use.htm (accessed 20 August 2007).
5. Poovorawan Y., Theamboonlers A., Vimolket T., Sinlaparatsamee S., Chaiear K., Siraprapasiri T. et al. Impact of HBV immunization as part of the EPI. Vaccine 2000 19:943 9.
6. Vanichseni S., Kitayaporn D., Mastro T. D., Mock P. A., Raktham S., Des Jarlais D. C. et al. Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand. AIDS 2001 15:397 405.
7. Ratanasuwan W., Sonji A., Tiengrim S., Techasathit W., Suwanagool S. Serological survey of viral hepatitis A, B and C at Thai central region and Bangkok: a population based study. Southeast Asian J Trop Med Public Health 2004 35:416 20.
8. Soogarun S., Wiwanitkit V. Vaccinating Thai adolescents against hepatitis A: is it cost-effective? Southeast Asian J Trop Med Public Health 2002 33:145 8.
9. O'Donovan D., Cooke R., Joce R., Eastbury A., Waite J., Stene-Johansen K. An outbreak of hepatitis A amongst injecting drug users. Epidemiol Infect 2001 127:469 73.
10. Wattana W., van Griensven F., Rhucharoenpornpanich O., Manopaiboon C., Thienkrua W., Bannatham R. et al. Respondent-driven sampling to assess characteristics and estimate the number of injection drug users in Bangkok, Thailand. Drug Alcohol Depend 2007 90:228 33.
11. Murrill C., Weeks H., Castrucci B., Weinstock H. S., Bell B. P., Spruill C. et al. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drugs users admitted to drug treatment in 6 US cities. Am J Public Health 2002 92:385 7.
12. Garfein R., Vlahov D., Galai N., Doherty M. C., Nelson K. E. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996 86:655 61.
13. Levine O. S., Vlahov D., Koehler J., Cohn S., Spronk A. M., Nelson K. E. Seroepidemiology of hepatitis B virus in a population of injection drug users: association with drug injecting patterns. Am J Epidemiol 1995 142:331 41.
14. Stark K., Bienzle U., Vonk R., Guggenmoos-Holzmann I. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. Int J Epidemiol 1997 26:1359 66.
15. Borg L., Khuri E., Wells A., Melia D., Bergasa N. V., Ho A. et al. Methadone maintained former heroin addicts, including those who are anti-HIV-1 seropositive, comply with and respond to hepatitis B vaccination. Addiction 1999 94:489 93.
16. Rodrigo J., Serra M., Aparisi L., Escudero A., Gilabert M. S., Garcia F. et al. Immune response to hepatitis B vaccine in parenteral drug abusers. Vaccine 1992 10:798 801.
17. Mezzelani P., Venturini L., Turrina G., Lugoboni F., Des Jarlais D. C. High compliance with a hepatitis B virus vaccination program among intravenous drug users [Letter J Infect Dis 1991 163:923.
18. Lugoboni F., Migliozzi S., Schiesari F., Pauletto N., Bovo G. L., Ciaffoni S. et al. Immunoresponse to hepatitis B vaccination and adherence campaign among injecting drug users. Vaccine 1997 15:1014 16.
19. Des Jarlais D., Fisher D., Newman J., Trubatch B. N., Yancovitz M., Paone D. et al. Providing hepatitis B vaccination to injection drug users: referral to health clinics vs. on-site vaccination at a syringe exchange program. Am J Public Health 2001 91:1791 2.
20. Lum P., Ochoa K., Hahn J., Page Shafer K., Evans J. L., Moss A. R. Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study. Am J Public Health 2003 93:919 23.
21. Zajac B. A., West D. J., McAleer W. J., Scolnick E. M. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 1986 13:39 45.
22. Andre F. E. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989 87:14S 20S.
23. Rumi M., Colombo M., Romeo R., Boschini A., Zanetti A., Gringeri A. et al. Suboptimal response to hepatitis B vaccine in drug user. Arch Intern Med 1991 151:574 8.
24. Dore G. J., Cooper D. A., Pozniak A. L., DeJesus E., Zhong L., Miller M. D. et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004 189:1185 92.
25. Jain M. K., Comanor L., White C., Kipnis P., Elkin C., Leung K. et al. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J Viral Hepat 2007 14:176 82.
26. Osborn M. K., Guest J. L., Rimland D. Hepatitis B virus and HIV coinfection: relationship of different serological patterns to survival and liver disease. HIV Med 2007 8:271 9.
27. Teppakdee A., Tangwitoon A., Khemasuwan D., Tangdhanakanond K., Suramaethakul N., Sriratanaban J. et al. Cost-benefit analysis of hepatitis A vaccination in Thailand. Southeast Asian J Trop Med Public Health 2002 33:118 27.
28. Soogarun S., Wiwanitkit V. Vaccinating Thai adolescents against hepatitis A: is it cost-effective? Southeast Asian J Trop Med Public Health 2002 33:145 8.
29. Collier A. C., Corey L., Murphy L. V., Handsfield H. H. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med 1988 109:101 5.
30. Keet I. P. M., van Doornum G., Safary A., Coutinho R. A. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. AIDS 1992 6:509 10.
31. Bruguera M., Cremades M., Salinas R., Costa J., Grau M., Sans J. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. J Clin Gastroenterol 1992 14:27 30.
32. Tayal S. C., Sankar K. N. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. AIDS 1994 8:558 9.
33. Wong E. K., Bodsworth N. J., Slade M. A., Mulhall B. P., Donovan B. Response to hepatitis B vaccination in a primary care setting: influence of HIV infection, CD4+ lymphocyte count and vaccination schedule. Int J STD AIDS 1996 7:490 4.
34. Rey D., Krantz V., Partisani M., Schmitt M. P., Meyer P., Libbrecht E. et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients: effects on HIV-1 viral load. Vaccine 2000 18:1161 5.
35. Health Resources and Services Administration. A Guide to Primary Care for People with HIV/AIDS, 2004 Edition. Available at: http://hab.hrsa.gov/tools/ primarycareguide/PCGchap10.htm (accessed 22 August 2007).
36. Bortan A., Shah S., Epstein M., McGowan J. The efficacy of high-dose hepatitis B vaccination in HIV-infected individuals. Paper presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention, 22-25 July 2007, Sydney, Australia. Available from: http://www.iasociety.org/Default.aspx?pageId=11&abstractId=200704887 (accessed 8 August 2008).